Cite
HARVARD Citation
Raina, P. et al. (2022). Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing–Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis. Journal of pharmacology and pharmacotherapeutics. 13 (1), pp. 14-23. [Online].